A Phase 3 interventional study of Celecoxib and Celecoxib in Arthritis, Juvenile Rheumatoid, sponsored by Pfizer. Completed at 58 sites in 15 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2008-05-30.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.
Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2002, is one of 4 in phase 3, and was the 3rd registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 2–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 127 across the 7 interventional studies, 100 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
2-18 years old with active JRA
Exclusion Criteria:
other experimental meds, recent changes in arthritis meds
Drug: Celecoxib
Drug: Celecoxib
Control comparator, 15 mg/kg/dy target dose
Drug: Naproxen
ACR Pediatric 30
Time frame: 12 weeks
Peds QOL
Time frame: 12 weeks
composites of acr 30
Time frame: 12 weeks
The record gives a start of Oct 2002, a primary completion of Apr 2004 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib